Drug Trial Radar · NCT04381936
Randomised Evaluation of COVID-19 Therapy
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70,000
Planned (sponsor's estimate)
Start
Mar 19, 2020
Primary completion
Sep 30, 2028
Study completion Sep 30, 2038
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- UK Research and Innovation; National Institute for Health Research, United Kingdom; Wellcome Trust; Bill and Melinda Gates Foundation; Department for International Development, United Kingdom; Health Data Research UK; Medical Research Council Population Health Research Unit; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections; Flu Lab
- First posted
- May 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only) Influenza: Baloxavir marboxil, Oseltamivir, Corticosteroids (dexamethasone) Community-acquired pneumonia: Corticosteroids (dexamethasone)
Conditions
- Pneumonia
Interventions
Lopinavir-RitonavirDrug
Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.
CorticosteroidDrug
Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or \>44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)
HydroxychloroquineDrug
Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).
AzithromycinDrug
Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.
Convalescent plasmaBiological
Single unit of ABO compatible convalescent plasma (275mls +/- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).
TocilizumabDrug
Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)
ImmunoglobulinBiological
Intravenous immunoglobulin (IVIg) for children \>44 weeks gestational age and \<18 years with PIMS-TS only (see Protocol for dosage)
Synthetic neutralising antibodiesDrug
Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation
AspirinDrug
150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.
ColchicineDrug
1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only
BaricitinibDrug
UK \[age ≥2 years with COVID pneumonia\] and India \[age ≥18 years with COVID-19 pneumonia\]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.
AnakinraDrug
For children ≥1 \<18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children \<10 kg in weight.
Dimethyl fumarateDrug
Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).
High Dose CorticosteroidDrug
Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.
EmpagliflozinDrug
Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).
SotrovimabDrug
UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.
MolnupiravirDrug
Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.
PaxlovidDrug
UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.
Baloxavir MarboxilDrug
Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection. 40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4.
OseltamivirDrug
Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection. 75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)
Corticosteroids (dexamethasone)Drug
Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations \<92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
Corticosteroids (dexamethasone)Drug
Patients ≥18 years old with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge)Time frame: Within 28 days after randomisation
- Influenza co-primary outcome: All-cause mortality (with subsidiary analysis of cause of death and death at various timepoints following discharge)Time frame: Within 28 days after randomisation
- Influenza co-primary outcome: Time to discharge alive from hospitalTime frame: Within the first 28-days
Locations
16 sites in 16 countries. Site status is shown where the registry gives one.
Belgian sites are managed by the European Clinical Research Alliance on Infectious Diseases
Brussels, Belgium · Recruiting
Estonian sites are managed by the European Clinical Research Alliance on Infectious Diseases
Tallinn, Estonia · Recruiting
French sites are managed by the European Clinical Research Alliance on Infectious Diseases
Paris, France · Recruiting
Kumasi Center for Collaborative Research in Tropical Medicine KNUST
Kumasi, Ghana · Recruiting
Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases
New Delhi, India · Completed
Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology
Jakarta, Indonesia · Recruiting
Italian sites are managed by the European Clinical Research Alliance on Infectious Diseases
Roma, Italy · Recruiting
Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences
Kathmandu, Nepal · Recruiting
Dutch sites are managed by the European Clinical Research Alliance on Infectious Diseases
Utrecht, Netherlands · Recruiting
Portuguese sites are managed by the European Clinical Research Alliance on Infectious Diseases
Lisbon, Portugal · Recruiting
Romanian sites are managed by the European Clinical Research Alliance on Infectious Diseases
Bucharest, Romania · Recruiting
Wits Health Consortium
Johannesburg, South Africa · Recruiting
Spanish sites are managed by the European Clinical Research Alliance on Infectious Diseases
Barcelona, Spain · Recruiting
Swedish sites are managed by the European Clinical Research Alliance on Infectious Diseases
Stockholm, Sweden · Recruiting
Nuffield Department of Population Health, University of Oxford
Oxford, United Kingdom · Recruiting
Oxford University Clinical Research Unit, Centre for Tropical Medicine
Ho Chi Minh City, Vietnam · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.